Admescope 2022 lookback
31 January 2023
2022 was full of action, and it marked the most successful year to date in Admescope’s history. We are grateful to our customers who trusted us to perform their studies and are proud to say that we contributed to the highest ever number of drug discovery and development projects for customers across the continents.Read more
I have become an Admescopian!
17 November 2022
Time goes by fast when having fun – such a cliché, and yet so true! It was a just over a year ago when I joined Admescope, and no doubt it has been one of the most memorable periods of my life so far.Read more
Meet the team: Part 3
7 July 2022
Admescope welcomes Dr Laszlo Szilagyi, the newest member of the Business Development team, who will support the EU and APAC activities with his broad pharma and CRO experience.Read more
Meet the team: Part 2
13 April 2022
As part of our ‘meet the team’ series, Admescope welcomes Leah Haydock, a new US-based member of the Business Development team. With over 15 years of experience in international business, sales and marketing at companies including Evans Medical, Smith & Nephew and Cynosure, Leah is excited to join the company and put her background in pharmacology to good use.Read more
MIST evaluation toolbox – what is in there? Part 4
25 February 2022
The overall aim of the safety metabolism studies is to better understand human metabolism. How is the drug cleared, what metabolites are formed, what is the relative exposure to these and can they be considered safety tested through adequate exposures in toxicology species. The 4th part of this blog series concerns the MIST analysis, i.e. the metabolite exposure comparison performed utilising samples from repeated dose studies in man and toxicology species.Read more
